What was the market valuation of the US acute agitation-aggression-treatment market in 2024?

The market valuation was $1307.17 Million in 2024. Read More

What is the projected market valuation for the US acute agitation-aggression-treatment market by 2035?

The projected valuation for 2035 is $2737.77 Million. Read More

What is the expected CAGR for the US acute agitation-aggression-treatment market during the forecast period 2025 - 2035?

The expected CAGR is 6.95% during the forecast period 2025 - 2035. Read More

Which drug class had the highest valuation in the US acute agitation-aggression-treatment market?

The Second-Generation Anti-Psychotics had a valuation range of $500.0 Million to $1100.0 Million. Read More

What are the primary routes of administration for treatments in the US acute agitation-aggression-treatment market?

The primary routes of administration include Oral, with a valuation range of $400.0 Million to $850.0 Million, and Intramuscular, ranging from $700.0 Million to $1500.0 Million. Read More

Which indication had the highest market valuation in the US acute agitation-aggression-treatment market?

Drug-induced Agitation and Aggression had a valuation range of $250.0 Million to $500.0 Million. Read More

What is the market size for hospitals and clinics as end users in the US acute agitation-aggression-treatment market?

The market size for hospitals and clinics as end users ranged from $600.0 Million to $1200.0 Million. Read More

Who are the key players in the US acute agitation-aggression-treatment market?

Key players include Johnson & Johnson, Pfizer Inc, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Roche Holding AG, Novartis AG, and Otsuka Pharmaceutical Co Ltd. Read More

What is the market valuation range for Benzodiazepines in the US acute agitation-aggression-treatment market?

The market valuation range for Benzodiazepines is $300.0 Million to $600.0 Million. Read More

What is the expected growth trend for the US acute agitation-aggression-treatment market in the coming years?

The market is expected to grow steadily, with a projected valuation increase to $2737.77 Million by 2035. Read More

US Acute Agitation Aggression Treatment Market

ID: MRFR/Pharma/15218-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Acute Agitation Aggression Treatment Market Research Report: Size, Share, Trend Analysis By Drug Class (First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Others), By Route of Administration (Oral, Intramuscular, Others), By Indication (Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-induced Agitation and Aggression, Alcohol Withdrawal, Others) and By End Users (Hospitals & Clinics, Psychiatric Care Facilities, Others) - Growth Outlook & Industry Forecast 2025 To 2035

US Acute Agitation Aggression Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Drug Class (USD Million)
  1. 4.1.1 First-Generation Anti-Psychotics
  2. 4.1.2 Second-Generation Anti-Psychotics
  3. 4.1.3 Benzodiazepines
  4. 4.1.4 Others
2. 4.2 Healthcare, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Intramuscular
  3. 4.2.3 Others
3. 4.3 Healthcare, BY Indication (USD Million)
  1. 4.3.1 Schizophrenia
  2. 4.3.2 Dementia
  3. 4.3.3 Bipolar Disorder
  4. 4.3.4 Depression
  5. 4.3.5 Drug-induced Agitation and Aggression
  6. 4.3.6 Alcohol Withdrawal
  7. 4.3.7 Others
4. 4.4 Healthcare, BY End User (USD Million)
  1. 4.4.1 Hospitals & Clinics
  2. 4.4.2 Psychiatric Care Facilities
  3. 4.4.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Johnson & Johnson (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer Inc (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Eli Lilly and Company (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Roche Holding AG (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis AG (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Otsuka Pharmaceutical Co Ltd (JP)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DRUG CLASS
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY INDICATION
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Million)
14. 6.14 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
18. 6.18 HEALTHCARE, BY END USER, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Drug Class (USD Million, 2025-2035)

First-Generation Anti-Psychotics
Second-Generation Anti-Psychotics
Benzodiazepines
Others

Healthcare By Route of Administration (USD Million, 2025-2035)

Oral
Intramuscular
Others

Healthcare By Indication (USD Million, 2025-2035)

Schizophrenia
Dementia
Bipolar Disorder
Depression
Drug-induced Agitation and Aggression
Alcohol Withdrawal
Others

Healthcare By End User (USD Million, 2025-2035)

Hospitals & Clinics
Psychiatric Care Facilities
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”